EpiCept Corporation Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Englewood Cliffs NJ United States (1993)
Status: Acquired by Immune Pharmaceuticals (2012) → now United General Ltd (2021)

Organization Overview

First Clinical Trial
2006
NCT00423410
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (2)

Key: EpiCept Corporation (0) Acquired (2)

aldesleukin (proleukin) (4 trials)

histamine dihydrochloride (4 trials)

Drugs in Phase 2 Trials (4)

amitriptyline (elavil) (2 trials)

azacitidine (vidaza) (1 trial)

gabapentin (neurontin) (1 trial)

ketamine (ketalar) (2 trials)

Drugs in Phase 1 Trials (1)

crinobulin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 2)

Leukemia (Phase 4)

Leukemia, Myeloid (Phase 4)

Leukemia, Myeloid, Acute (Phase 4)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 7